Anti-obesity meds can expand the market for weight loss surgery: Bernstein

seekingalpha01-22

The rising popularity of the GLP-1 class of anti-obesity medications developed by Novo Nordisk (NVO) and Eli Lilly (LLY) can expand the market for weight loss surgeries in the long run, Bernstein said...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2405393093?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-01-22 01:00","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2405393093","market":"us","top_or_hot":-1,"title":"Anti-obesity meds can expand the market for weight loss surgery: Bernstein","media":"seekingalpha","content":"<div>\n<p>The rising popularity of the GLP-1 class of anti-obesity medications developed by Novo Nordisk (NVO) and Eli Lilly (LLY) can expand the market for weight loss surgeries in the long run, Bernstein said...</p>\n\n<a href=\"https://seekingalpha.com/news/4056663-glp-1s-can-expand-market-weight-loss-surgery-bernstein\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Anti-obesity meds can expand the market for weight loss surgery: Bernstein</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnti-obesity meds can expand the market for weight loss surgery: Bernstein\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-22 01:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4056663-glp-1s-can-expand-market-weight-loss-surgery-bernstein><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The rising popularity of the GLP-1 class of anti-obesity medications developed by Novo Nordisk (NVO) and Eli Lilly (LLY) can expand the market for weight loss surgeries in the long run, Bernstein said...</p>\n\n<a href=\"https://seekingalpha.com/news/4056663-glp-1s-can-expand-market-weight-loss-surgery-bernstein\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SYK","symbol_name":"史赛克","start_time":0,"source_url":"https://seekingalpha.com/news/4056663-glp-1s-can-expand-market-weight-loss-surgery-bernstein","article_id":"2405393093","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2405393093","pubTimestamp":1705856401,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"The rising popularity of the GLP-1 class of anti-obesity medications developed by Novo Nordisk (NVO) and Eli Lilly (LLY) can expand the market for weight loss surgeries in the long run, Bernstein said","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SYK":"史赛克","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1917777945.USD":"安联专题基金Cl AT Acc","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0058720904.USD":"联博国际健康护理基金A","LU0079474960.USD":"联博美国增长基金A","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","BK4568":"美国抗疫概念","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","JNJ":"强生","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC","BK4581":"高盛持仓","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4504":"桥水持仓","LU0211326755.USD":"TEMPLETON GLOBAL INCOME \"A\" (USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","MDT":"美敦力","LU1261432733.SGD":"Fidelity World A-ACC-SGD","NONOF":"Novo-Nordisk A/S","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","ISRG":"直觉外科公司","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","RSLS":"ReShape Lifesciences, Inc.","BK4592":"伊斯兰概念","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","NVO":"诺和诺德","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LLY":"礼来","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4566":"资本集团","LU0496365809.HKD":"TEMPLETON GLOBAL INCOME \"A\" (HKD) INC (Q)"},"translate_title":"抗肥胖药物可以扩大减肥手术市场：伯恩斯坦","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SYK":1,"MDT":1,"NONOF":1,"LLY":1,"JNJ":1,"ISRG":1,"NVO":1,"RSLS":1},"content_text":"The rising popularity of the GLP-1 class of anti-obesity medications developed by Novo Nordisk (NVO) and Eli Lilly (LLY) can expand the market for weight loss surgeries in the long run, Bernstein said in a research note last week. Lilly (LLY) and Novo (OTCPK:NONOF) treatments marketed as Wegovy and Zepbound, respectively, for obesity, have long been cited as a reason for a decline in the number of bariatric procedures performed to help patients lose weight. Citing a survey of 50 bariatric surgeons in the U.S., Bernstein analysts led by Lee Hambright noted that since the hype of GLP-1 drugs began, the average number of weight loss procedures has dropped ~11%. Some of the leading operators in the market, including Intuitive Surgical (NASDAQ:ISRG), Medtronic (NYSE:MDT), and Johnson & Johnson (NYSE:JNJ), have indicated broadly similar observations. Shares of Intuitive Surgical (ISRG), Medtronic (MDT), and ReShape Lifesciences (RSLS) came under pressure in October after JNJ CEO Joaquin Duato noted that GLP-1s are having at least a near-term impact on weight loss surgeries. \"We're seeing some impact in our bariatric business in the short term. Some patients are reconsidering surgery, expecting to get treatment,\" Duato said during the company's Q3 2023 earnings call. Despite some pressure on surgery volumes in the near term, Bernstein argues that there is still no consensus on the extent of long-term impact. \"Concluding that the rise of weight loss meds will come at the expense of bariatric procedures may be jumping the gun,\" they added. While there are questions about the future demand for GLP-1s amid concerns about affordability, coverage, side effects, and long-term drug adherence, the analysts opined that weight loss surgeries are getting safer, quicker, more effective, and less costly. On the other hand, GLP-1 drugs can make more patients eligible for bariatric surgery by helping them reach a safer BMI profile, according to Bernstein's note on Friday. \"By helping very obese patients lose some weight, GLP-1 drugs not only reduce risk from bariatric surgery for such patients, but also help make them eligible for weight loss procedures they didn't previously quality for because of their dangerously high BMI,\" Hambright and the team added. MedTech firms such as Stryker (NYSE:SYK), which operates in the knee surgery market, have indicated a \"neutral to slightly positive\" impact on procedure volumes as weight loss drugs help patients get to a safer BMI level.  On the other hand, the recent hype around GLP-1 drugs can increase public awareness of obesity as a chronic disease and inform patients about the entire gamut of treatment options, including surgery. \"In the end, GLP-1s might actually serve as a tailwind to bariatric surgery growth over the longer term,\" Bernstein concluded.  More on Intuitive Surgical, J&J, etc.  Medtronic: Hugo's Global Rollout Is Positive; GLP-1 Is Negative Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Earnings week ahead: Tesla, Netflix, AT&T, Johnson & Johnson, GE and more Johnson & Johnson wins full FDA approval for bladder cancer therapy Balversa","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2405393093"}